Therapy of early chronic phase chronic myelogenous leukemia (CML) with SCH54031 (PEG interferon alpha 2B/PEG intron) and low-dose cytosine arabinoside (Ara-C).

Trial Profile

Therapy of early chronic phase chronic myelogenous leukemia (CML) with SCH54031 (PEG interferon alpha 2B/PEG intron) and low-dose cytosine arabinoside (Ara-C).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Cytarabine
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center
    • 06 Jun 2013 Planned End Date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 27 Aug 2012 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top